A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

被引：0
|
作者：
Mulligan, Stephen P. [1 ,2 ,3 ]
Gill, Devinder [4 ]
Turner, Paul [5 ]
Renwick, William E. P. [6 ]
Latimer, Maya [7 ]
Mackinlay, Naomi [1 ]
Berkahn, Leanne [8 ]
Simpson, David [9 ]
Campbell, Philip [10 ]
Forsyth, Cecily J. [11 ]
Cull, Gavin [12 ]
Harrup, Rosemary [13 ]
Sulda, Melanie [14 ]
Best, Giles [15 ]
Bressel, Mathias [16 ]
Di Iulio, Juliana [16 ]
Kuss, Bryone J. [14 ,17 ]
机构：
[1] Royal N Shore Hosp, Sydney, NSW, Australia
[2] CLL Australian Res Consortium CLLARC, Sydney, NSW, Australia
[3] Australasian Leukaemia & Lymphoma Grp ALLG, Melbourne, Australia
[4] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[5] Austin Hosp, Melbourne, Vic 3084, Australia
[6] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
[7] Canberra Hosp, Canberra, ACT, Australia
[8] Auckland Hosp, Auckland, New Zealand
[9] North Shore Hosp, Auckland, New Zealand
[10] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia
[11] Gosford Hosp, Gosford, Australia
[12] Sir Charles Gairdner Hosp, Perth, WA, Australia
[13] Royal Hobart Hosp, Hobart, Tas, Australia
[14] Flinders Med Ctr, Adelaide, SA, Australia
[15] Univ Sydney, Kolling Inst, Sydney, NSW 2006, Australia
[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[17] Flinders Univ S Australia, Adelaide, SA 5001, Australia
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 42 条
  • [31] Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fludarabine and cyclophosphamide) in previously untreated patients aged 65-70 years with advanced stage chronic lymphocytic leukemia (CLL):: A phase II trial of the FCGCLL/MW.
    Delmer, Alain
    Lepretre, Stephane
    Cazin, Bruno
    Feugier, Pierre
    Tournilhac, Olivier
    Leporrier, Michel
    Dreyfus, Brigitte
    Mahe, Beatrice
    Thieblemont, Catherine
    Divine, Marine
    Levy, Vincent
    Leblond, Veronique
    Cymbalista, Florence
    Letestu, Remy
    BLOOD, 2006, 108 (11) : 801A - 801A
  • [32] Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
    Egle, Alexander
    Weiss, Lukas
    Russ, Gudrun
    Thoedtmann, Ralf
    Pleyer, Lisa
    Gastl, Guenther
    Thaler, Josef
    Petzer, Andreas
    Tinhofer, Inge
    Greil, Richard
    BLOOD, 2007, 110 (11) : 609A - 609A
  • [33] Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect VR CLL cohort study
    Flowers, Christopher R.
    Nabhan, Chadi
    Kay, Neil E.
    Mato, Anthony
    Lamanna, Nicole
    Farber, Charles M.
    Davids, Matthew S.
    Kiselev, Pavel
    Swern, Arlene S.
    Sullivan, Kristen
    Flick, E. Dawn
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2327 - 2335
  • [34] Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara
    Fink, Anna Maria
    Busch, Raymonde
    Kovacs, Gabor
    Maurer, Christian
    Lange, Elisabeth
    Koeppler, Hubert
    Kiehl, Michael G.
    Soekler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Koechling, Georg R. A.
    Ploeger, Christoph
    Gregor, Michael
    Plesner, Torben
    Trneny, Marek
    Fischer, Kirsten
    Doehner, Hartmut
    Kneba, Michael
    Wendtner, Clemens-Martin
    Klapper, Wolfram
    Kreuzer, Karl Anton
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Hallek, Michael
    BLOOD, 2014, 124 (21)
  • [35] Influence of chromosomal aberrations on response to first line therapy in B-cell chronic lymphocytic leukemia: Interim analysis of PALG-CLL3 randomized study comparing cladribine plus cyclophosphamide vs fludarabine plus cyclophosphamide
    Robak, Tadcusz
    Blonski, Jerzy Z.
    Wawrzyniak, Ewa
    Palacz, Aleksandra
    Gora-Tybor, Joanna
    Jamroziak, Krzysztof
    Piszcz, Jaroslaw
    Kloczko, Janusz S.
    Koczkodaj, Dorota
    Kowal, Malgorzata
    Dmoszynska, Anna
    Mital, Andrzej
    Hellman, Andrzej
    BLOOD, 2007, 110 (11) : 610A - 610A
  • [36] Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial (vol 3, pg e323, 2016)
    Greil, R.
    Obrtlikova, P.
    Smolej, L.
    Lancet Haematology, 2016, 3 (08): : E361 - E361
  • [37] Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup
    Dartigeas, Caroline
    Van Den Neste, Eric
    Berthou, Christian
    Maisonneuve, Herve
    Lepretre, Stephane
    Dilhuydy, Marie-Sarah
    Bene, Marie-Christine
    Nguyen-Khac, Florence
    Letestu, Remi
    Cymbalista, Florence
    De Guibert, Sophie
    Aurran, Therese
    Laribi, Kamel
    Vilque, Jean Pierre
    Tournilhac, Olivier
    Delmer, Alain
    Feugier, Pierre
    Cazin, Bruno
    Michallet, Anne-Sophie
    Levy, Vincent
    Troussard, Xavier
    Delepine, Roselyne
    Giraudeau, Bruno
    Colombat, Philippe
    Leblond, Veronique
    BLOOD, 2012, 120 (21)
  • [38] Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil:: Interim analysis of a phase III study of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Stauch, M
    Kneba, M
    Ritgen, M
    Söling, U
    Burkhard, O
    Bergmann, M
    Wendtner, CM
    Hiddemann, W
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 109A - 109A
  • [39] First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzano, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John F.
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Fischer, Kirsten
    BLOOD, 2009, 114 (22) : 223 - 224
  • [40] Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC plus G) Versus Chlorambucil Plus Obinutuzumab (Cbl plus G) As Front-Line Therapy
    Mulligan, Stephen P.
    Freeman, Jane A.
    Badoux, Xavier
    Eek, Richard
    Cull, Gavin
    Mackinlay, Naomi J.
    Murphy, Nicholas E.
    Carradice, Duncan P.
    Solterbeck, Ann C.
    Best, Oliver Giles
    Tam, Constantine S.
    Kuss, Bryone J.
    BLOOD, 2018, 132
12345